FHC, Inc., a global manufacturer of products for the neuroscience industry, has announced the acquisition of Atanse, a medical device company developing products for intracerebral drug delivery.
FHC and Atanse have been partners since Atanse’s founding in 2010. Dr. Miles Cunningham, Atanse’s founder and Chief Scientific Officer, first partnered with FHC to collaborate on research funded by the National Institutes of Health’s Small Business Innovation Research (SBIR) program.
The acquisition adds a complementary technology that will support continued growth of FHC’s existing product lines. Functional neurosurgeons, the primary consumers of FHC products, are engaged in ongoing clinical trials for new therapies that require direct injection into the brain. Atanse’s radial microcannula technology will be integrated with FHC’s existing microTargeting™ stereotactic platforms, STar™ Drive positioning devices, and WayPoint™ surgical planning software to facilitate these procedures and provide a complete system for accurate intracerebral drug delivery.
“FHC’s mission is to provide innovative neurosurgical solutions that meet the evolving needs of our customers,” said Fred Haer, FHC’s President and CEO. “We welcome the Atanse team to FHC and look forward to advancing this exciting technology.”